Equities

Vistagen Therapeutics Inc

VTGN:NAQ

Vistagen Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.00
  • Today's Change0.005 / 0.17%
  • Shares traded175.60k
  • 1 Year change-46.43%
  • Beta0.8063
Data delayed at least 15 minutes, as of Sep 19 2024 20:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy3
Outperform1
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 3 analysts offering 12 month price targets for Vistagen Therapeutics Inc have a median target of 12.00, with a high estimate of 15.00 and a low estimate of 12.00. The median estimate represents a 300.00% increase from the last price of 3.00.
High400.0%15.00
Med300.0%12.00
Low300.0%12.00

Earnings history & estimates in USD

On Aug 13, 2024, Vistagen Therapeutics Inc reported 1st quarter 2025 losses of -0.35 per share.
The next earnings announcement is expected on Nov 07, 2024.
Average growth rate+18.83%
Vistagen Therapeutics Inc reported annual 2024 losses of -1.52 per share on Jun 11, 2024.
Average growth rate+29.90%
More ▼

Revenue history & estimates in USD

VistaGen Therapeutics, Inc. had 1st quarter 2025 revenues of 84.00k. This missed the 300.00k consensus estimate of the 2 analysts following the company. This was 69.78% below the prior year's 1st quarter results.
Average growth rate-0.91%
VistaGen Therapeutics, Inc. had revenues for the full year 2024 of 1.06m. Last year the company did not report any revenues.
Average growth rate-0.74%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.